Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer.
Immune checkpoint inhibitor
Immunotherapy
Ovarian cancer
PARP inhibitors
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
received:
02
06
2024
accepted:
04
08
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
21
8
2024
Statut:
epublish
Résumé
The advent of polyadenosine diphosphate ribose polymerase inhibitors (PARPi) has brought about significant changes in the field of ovarian cancer treatment. However, in 2022, Rucaparib, Olaparib, and Niraparib, had their marketing approval revoked for third-line and subsequent therapies due to an increased potential for adverse events. Consequently, the exploration of new treatment modalities remains imperative. Recently, the integration of PARPi with immune checkpoint inhibitors (ICIs) has emerged as a potential remedy option within the context of ovarian cancer. This article offers a comprehensive examination of the mechanisms and applications of PARPi and ICIs in the treatment of ovarian cancer. It synthesizes the existing evidence supporting their combined use and discusses key considerations that merit attention in ongoing development efforts.
Identifiants
pubmed: 39169400
doi: 10.1186/s12967-024-05583-z
pii: 10.1186/s12967-024-05583-z
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
778Subventions
Organisme : Research Team for Reproduction Health and Translational Medicine of Hunan Normal University
ID : 2023JC101
Organisme : Key Research and Development Program of Hunan Province of China
ID : 2022XKQ0205
Organisme : National Natural Science Foundation of China
ID : 81874193
Organisme : National Natural Science Foundation of China
ID : 82003050
Organisme : Hunan Provincial Natural Science Foundation of China
ID : 2023JJ30375
Organisme : Hunan Provincial Natural Science Foundation of China
ID : 2023JJ40415
Organisme : Hunan Provincial Natural Science Foundation of China
ID : 2024JJ5285
Organisme : Hunan Provincial Key Laboratory of Materials Protection for Electric Power and Transportation, Changsha University of Science and Technology
ID : B2023047708
Organisme : the Hunan Provincial Science and Technology Department
ID : 2023ZJ1120
Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
pubmed: 36633525
doi: 10.3322/caac.21763
Goh J, Mohan GR, Ladwa R, Ananda S, Cohen PA, Baron-Hay S. Frontline treatment of epithelial ovarian cancer. Asia Pac J Clin Oncol. 2015;11(Suppl 6):1–16.
pubmed: 26669253
doi: 10.1111/ajco.12449
Provencher DM, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Brundage M, et al. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann Oncol. 2018;29(2):431–8.
pubmed: 29186319
doi: 10.1093/annonc/mdx754
Zhang J, Li XB, Ji ZH, Ma R, Bai WP, Li Y. Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients. Biomed Res Int. 2021, 2021: 5533134.
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304.
pubmed: 31099893
doi: 10.3322/caac.21559
Pujade-Lauraine E, Banerjee S, Pignata S. Management of Platinum-Resistant, relapsed epithelial ovarian Cancer and New Drug perspectives. J Clin Oncol. 2019;37(27):2437–48.
pubmed: 31403868
doi: 10.1200/JCO.19.00194
Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020;19(10):711–36.
pubmed: 32884152
doi: 10.1038/s41573-020-0076-6
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.
pubmed: 15829966
doi: 10.1038/nature03443
Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391–402.
pubmed: 31562799
doi: 10.1056/NEJMoa1910962
Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022;166(2):219–29.
pubmed: 35690498
doi: 10.1016/j.ygyno.2022.05.020
Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, et al. Multi-maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant high-Grade Serous Ovarian Cancer (MOLTO): a phase II trial. Clin Cancer Res. 2023;29(14):2602–11.
pubmed: 36799931
doi: 10.1158/1078-0432.CCR-22-3282
Gao Q, Zhu J, Zhao W, Huang Y, An R, Zheng H, et al. Olaparib Maintenance Monotherapy in Asian patients with platinum-sensitive relapsed ovarian Cancer: phase III trial (L-MOCA). Clin Cancer Res. 2022;28(11):2278–85.
pubmed: 35131903
pmcid: 9359747
doi: 10.1158/1078-0432.CCR-21-3023
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.
pubmed: 22452356
doi: 10.1056/NEJMoa1105535
Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18(12):773–91.
pubmed: 34285417
doi: 10.1038/s41571-021-00532-x
Markham A, Pamiparib. First Approval Drugs. 2021;81(11):1343–8.
pubmed: 34287805
Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M et al. PARP inhibitors in ovarian Cancer: the Route to Ithaca. Diagnostics (Basel) 2019, 9(2).
Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzinski M, et al. Olaparib Versus Nonplatinum Chemotherapy in patients with platinum-sensitive relapsed ovarian Cancer and a germline BRCA1/2 mutation (SOLO3): a Randomized Phase III Trial. J Clin Oncol. 2020;38(11):1164–74.
pubmed: 32073956
pmcid: 7145583
doi: 10.1200/JCO.19.02745
Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018;19(8):1117–25.
pubmed: 30026000
doi: 10.1016/S1470-2045(18)30333-4
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61.
pubmed: 28916367
pmcid: 5901715
doi: 10.1016/S0140-6736(17)32440-6
Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51.
pubmed: 31345627
doi: 10.1016/S1470-2045(19)30388-2
Middleton G, Brock K, Savage J, Mant R, Summers Y, Connibear J, et al. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med. 2020;8(9):895–904.
pubmed: 32199466
doi: 10.1016/S2213-2600(20)30033-3
Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R, et al. Pembrolizumab as Neoadjuvant Therapy before Radical Cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an Open-Label, Single-Arm, phase II study. J Clin Oncol. 2018;36(34):3353–60.
pubmed: 30343614
doi: 10.1200/JCO.18.01148
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717–26.
pubmed: 27157491
doi: 10.1016/S1470-2045(16)00175-3
Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, et al. Lenvatinib plus Pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711–8.
pubmed: 30922731
doi: 10.1016/S1470-2045(19)30020-8
Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-Dependent Immune response and enhances the therapeutic efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res. 2019;79(2):311–9.
pubmed: 30482774
doi: 10.1158/0008-5472.CAN-18-1003
Vikas P, Borcherding N, Chennamadhavuni A, Garje R. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol. 2020;10:570.
pubmed: 32457830
pmcid: 7228136
doi: 10.3389/fonc.2020.00570
Li T, Wang X, Qin S, Chen B, Yi M, Zhou J. Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies. Biomed Pharmacother. 2023;162:114712.
pubmed: 37075667
doi: 10.1016/j.biopha.2023.114712
Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer 2023.
Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer. 2011;11(6):450–7.
pubmed: 21593786
pmcid: 4007007
doi: 10.1038/nrc3063
D’Amours D, Desnoyers S, D’Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999;342(Pt 2):249–68.
pubmed: 10455009
pmcid: 1220459
doi: 10.1042/bj3420249
Jalal S, Earley JN, Turchi JJ. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res. 2011;17(22):6973–84.
pubmed: 21908578
pmcid: 3218201
doi: 10.1158/1078-0432.CCR-11-0761
Luscher B, Ahel I, Altmeyer M, Ashworth A, Bai P, Chang P, et al. ADP-ribosyltransferases, an update on function and nomenclature. FEBS J. 2022;289(23):7399–410.
pubmed: 34323016
doi: 10.1111/febs.16142
Zong C, Zhu T, He J, Huang R, Jia R, Shen J. PARP mediated DNA damage response, genomic stability and immune responses. Int J Cancer. 2022;150(11):1745–59.
pubmed: 34952967
doi: 10.1002/ijc.33918
Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129(6):904–16.
pubmed: 37430137
pmcid: 10491787
doi: 10.1038/s41416-023-02326-7
Kyo S, Kanno K, Takakura M, Yamashita H, Ishikawa M, Ishibashi T et al. Clinical Landscape of PARP inhibitors in Ovarian Cancer: Molecular mechanisms and clues to overcome resistance. Cancers (Basel) 2022, 14(10).
Rass E, Willaume S, Bertrand P. 53BP1: keeping it under control, even at a Distance from DNA damage. Genes (Basel) 2022, 13(12).
Min A, Im SA. PARP inhibitors as therapeutics: beyond modulation of PARylation. Cancers (Basel) 2020, 12(2).
Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–8.
pubmed: 28302823
pmcid: 6175050
doi: 10.1126/science.aam7344
Cecere SC, Casartelli C, Forte M, Pignata S, Pisano C. Safety of PARP inhibitors as maintenance therapy in ovarian cancer. Expert Opin Drug Saf. 2023;22(10):897–908.
pubmed: 37668154
doi: 10.1080/14740338.2023.2254699
Chelariu-Raicu A, Trillsch F, Burges A, Czogalla B, Hester A, Wuerstlein R, et al. PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. Int J Gynecol Cancer. 2023;33(5):812–22.
pubmed: 36707086
doi: 10.1136/ijgc-2022-003990
Tian X, Chen L, Gai D, He S, Jiang X, Zhang N. Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS. Front Pharmacol. 2022;13:851246.
pubmed: 35401230
pmcid: 8990839
doi: 10.3389/fphar.2022.851246
Zhao D, Long X, Wang J. Dose Adjustment of Poly (ADP–Ribose) polymerase inhibitors in patients with hepatic or renal impairment. Drug Des Devel Ther. 2022;16:3947–55.
pubmed: 36405648
pmcid: 9673935
doi: 10.2147/DDDT.S387920
Varol U, Kucukzeybek Y, Alacacioglu A, Somali I, Altun Z, Aktas S, et al. BRCA genes: BRCA 1 and BRCA 2. J BUON. 2018;23(4):862–6.
pubmed: 30358186
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.
pubmed: 19553641
doi: 10.1056/NEJMoa0900212
Wang Y, Zheng K, Huang Y, Xiong H, Su J, Chen R, et al. PARP inhibitors in gastric cancer: beacon of hope. J Exp Clin Cancer Res. 2021;40(1):211.
pubmed: 34167572
pmcid: 8228511
doi: 10.1186/s13046-021-02005-6
Shao C, Wan J, Lam FC, Tang H, Marley AR, Song Y, et al. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies. Environ Mol Mutagen. 2022;63(6):308–16.
pubmed: 36054589
doi: 10.1002/em.22505
O’Malley DM. New therapies for Ovarian Cancer. J Natl Compr Canc Netw. 2019;17(55):619–21.
pubmed: 31117037
Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721–31.
pubmed: 34715071
doi: 10.1016/S1470-2045(21)00531-3
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-Year Follow-Up in patients with newly diagnosed Advanced Ovarian Cancer and a BRCA mutation: the SOLO1/GOG 3004 Trial. J Clin Oncol. 2023;41(3):609–17.
pubmed: 36082969
doi: 10.1200/JCO.22.01549
Li N, Zhu J, Yin R, Wang J, Pan L, Kong B et al. Treatment with Niraparib Maintenance Therapy in patients with newly diagnosed Advanced Ovarian Cancer: a phase 3 Randomized Clinical Trial. JAMA Oncol 2023.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84.
pubmed: 28754483
doi: 10.1016/S1470-2045(17)30469-2
Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, et al. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecol Oncol. 2022;164(3):498–504.
pubmed: 35063276
doi: 10.1016/j.ygyno.2021.12.025
Wu XH, Zhu JQ, Yin RT, Yang JX, Liu JH, Wang J, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial(☆). Ann Oncol. 2021;32(4):512–21.
pubmed: 33453391
doi: 10.1016/j.annonc.2020.12.018
Chan JK, Liu J, Song J, Xiang C, Wu EQ, Kalilani L, et al. Real-world trends of PARPi maintenance treatment uptake and progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the United States. J Clin Oncol. 2022;40(16suppl):6580–6580.
doi: 10.1200/JCO.2022.40.16_suppl.6580
Chan JK, Liu J, Song J, Xiang C, Wu E, Kalilani L, et al. Real-world outcomes Associated with Poly(ADP-ribose) polymerase inhibitor monotherapy maintenance in patients with primary Advanced Ovarian Cancer. Am J Clin Oncol. 2023;46(7):314–22.
pubmed: 37106485
pmcid: 10281176
doi: 10.1097/COC.0000000000001010
Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(4):465–78.
pubmed: 35298906
doi: 10.1016/S1470-2045(22)00122-X
Lee JY, Lee YY, Park JY, Shim SH, Kim SI, Kong TW, et al. Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3. J Gynecol Oncol. 2023;34(2):e51.
pubmed: 36890294
pmcid: 9995865
doi: 10.3802/jgo.2023.34.e51
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.
pubmed: 21436444
doi: 10.1126/science.1203486
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.
pubmed: 32612154
pmcid: 7395159
doi: 10.1038/s41423-020-0488-6
Bagchi S, Yuan R, Engleman EG. Immune Checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49.
pubmed: 33197221
doi: 10.1146/annurev-pathol-042020-042741
Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156.
pubmed: 34579759
pmcid: 8475356
doi: 10.1186/s13045-021-01164-5
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in Cancer: mechanisms of Action, Efficacy, and limitations. Front Oncol. 2018;8:86.
pubmed: 29644214
pmcid: 5883082
doi: 10.3389/fonc.2018.00086
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
pubmed: 18173375
pmcid: 10637733
doi: 10.1146/annurev.immunol.26.021607.090331
Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739–45.
pubmed: 17195077
doi: 10.1007/s00262-006-0272-1
Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med. 2011;84(4):409–21.
pubmed: 22180678
pmcid: 3238327
Mahoney KM, Freeman GJ, McDermott DF. The Next Immune-Checkpoint inhibitors: PD-1/PD-L1 blockade in Melanoma. Clin Ther. 2015;37(4):764–82.
pubmed: 25823918
pmcid: 4497957
doi: 10.1016/j.clinthera.2015.02.018
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
pubmed: 22437870
pmcid: 4856023
doi: 10.1038/nrc3239
Van Coillie S, Wiernicki B, Xu J. Molecular and Cellular functions of CTLA-4. Adv Exp Med Biol. 2020;1248:7–32.
pubmed: 32185705
doi: 10.1007/978-981-15-3266-5_2
Drakes ML, Mehrotra S, Aldulescu M, Potkul RK, Liu Y, Grisoli A, et al. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. J Ovarian Res. 2018;11(1):43.
pubmed: 29843813
pmcid: 5975524
doi: 10.1186/s13048-018-0414-z
Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016;7(2):1486–99.
pubmed: 26625204
doi: 10.18632/oncotarget.6429
Mortezaee K. Enriched cancer stem cells, dense stroma, and cold immunity: interrelated events in pancreatic cancer. J Biochem Mol Toxicol. 2021;35(4):e22708.
pubmed: 33491255
doi: 10.1002/jbt.22708
Mortezaee K, Najafi M. Immune system in cancer radiotherapy: resistance mechanisms and therapy perspectives. Crit Rev Oncol Hematol. 2021;157:103180.
pubmed: 33264717
doi: 10.1016/j.critrevonc.2020.103180
Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for Ovarian Cancer: adjuvant, combination, and Neoadjuvant. Front Immunol. 2020;11:577869.
pubmed: 33123161
pmcid: 7572849
doi: 10.3389/fimmu.2020.577869
Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.
doi: 10.1038/nature10166
Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127–33.
pubmed: 24071851
pmcid: 4320046
doi: 10.1038/ng.2762
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in patients with Noncolorectal high microsatellite Instability/Mismatch repair-deficient Cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.
pubmed: 31682550
doi: 10.1200/JCO.19.02105
O’Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, et al. Pembrolizumab in patients with microsatellite instability-high Advanced Endometrial Cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752–61.
pubmed: 34990208
pmcid: 8887941
doi: 10.1200/JCO.21.01874
Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA approval Summary: Pembrolizumab for the treatment of Tumor Mutational Burden-High Solid tumors. Clin Cancer Res. 2021;27(17):4685–9.
pubmed: 34083238
pmcid: 8416776
doi: 10.1158/1078-0432.CCR-21-0327
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, et al. Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian Cancer: phase 1b results from the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5(3):393–401.
pubmed: 30676622
pmcid: 6439837
doi: 10.1001/jamaoncol.2018.6258
Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080–7.
pubmed: 31046082
doi: 10.1093/annonc/mdz135
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22(7):1034–46.
pubmed: 34143970
doi: 10.1016/S1470-2045(21)00216-3
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. Atezolizumab, Bevacizumab, and Chemotherapy for newly diagnosed stage III or IV ovarian Cancer: placebo-controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39(17):1842–55.
pubmed: 33891472
pmcid: 8189598
doi: 10.1200/JCO.21.00306
Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for Cancer Immunotherapy-Blockade, Knockdown, or inhibition. Front Immunol. 2019;10:2022.
pubmed: 31507611
pmcid: 6718566
doi: 10.3389/fimmu.2019.02022
Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018;18(3):139–47.
pubmed: 29326431
pmcid: 6685071
doi: 10.1038/nrc.2017.117
Meng J, Peng J, Feng J, Maurer J, Li X, Li Y, et al. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. J Transl Med. 2021;19(1):415.
pubmed: 34620163
pmcid: 8499579
doi: 10.1186/s12967-021-03073-0
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. PARP inhibitor upregulates PD-L1 expression and enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017;23(14):3711–20.
pubmed: 28167507
pmcid: 5511572
doi: 10.1158/1078-0432.CCR-16-3215
Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, et al. PARP inhibition elicits STING-Dependent Antitumor immunity in Brca1-Deficient ovarian Cancer. Cell Rep. 2018;25(11):2972–e29802975.
pubmed: 30540933
pmcid: 6366450
doi: 10.1016/j.celrep.2018.11.054
Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN. GSK3beta: role in therapeutic landscape and development of modulators. Br J Pharmacol. 2010;160(1):1–19.
pubmed: 20331603
pmcid: 2860202
doi: 10.1111/j.1476-5381.2010.00661.x
Shiotani B, Zou L. Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks. Mol Cell. 2009;33(5):547–58.
pubmed: 19285939
pmcid: 2675165
doi: 10.1016/j.molcel.2009.01.024
Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8(1):1751.
pubmed: 29170499
pmcid: 5701012
doi: 10.1038/s41467-017-01883-9
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 Blockade synergizes therapeutically with PARP inhibition in BRCA1-Deficient ovarian Cancer. Cancer Immunol Res. 2015;3(11):1257–68.
pubmed: 26138335
pmcid: 4984269
doi: 10.1158/2326-6066.CIR-15-0044
Owen AM, Fults JB, Patil NK, Hernandez A, Bohannon JK. TLR agonists as mediators of trained immunity: mechanistic insight and immunotherapeutic potential to combat infection. Front Immunol. 2020;11:622614.
pubmed: 33679711
doi: 10.3389/fimmu.2020.622614
Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol. 2015;33:257–90.
pubmed: 25581309
pmcid: 5146691
doi: 10.1146/annurev-immunol-032414-112240
Ren Z, Yu Y, Chen C, Yang D, Ding T, Zhu L, et al. The triangle relationship between long noncoding RNA, RIG-I-like receptor signaling pathway, and Glycolysis. Front Microbiol. 2021;12:807737.
pubmed: 34917069
pmcid: 8670088
doi: 10.3389/fmicb.2021.807737
Jiang M, Chen P, Wang L, Li W, Chen B, Liu Y, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020;13(1):81.
pubmed: 32571374
pmcid: 7310007
doi: 10.1186/s13045-020-00916-z
Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, et al. PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. Oncoimmunology. 2022;11(1):2083755.
pubmed: 35756843
pmcid: 9225208
doi: 10.1080/2162402X.2022.2083755
Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via Intratumoral STING pathway activation in BRCA-Deficient models of triple-negative breast Cancer. Cancer Discov. 2019;9(6):722–37.
pubmed: 31015319
pmcid: 6548644
doi: 10.1158/2159-8290.CD-18-1218
Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553(7689):467–72.
pubmed: 29342134
pmcid: 5785464
doi: 10.1038/nature25432
Shakfa N, Li D, Nersesian S, Wilson-Sanchez J, Koti M. The STING pathway: therapeutic vulnerabilities in ovarian cancer. Br J Cancer. 2022;127(4):603–11.
pubmed: 35383278
pmcid: 9381712
doi: 10.1038/s41416-022-01797-4
Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19(1):136.
pubmed: 32887628
pmcid: 7472700
doi: 10.1186/s12943-020-01247-w
Turinetto M, Scotto G, Tuninetti V, Giannone G, Valabrega G. The role of PARP inhibitors in the Ovarian Cancer Microenvironment: moving Forward from Synthetic lethality. Front Oncol. 2021;11:689829.
pubmed: 34195090
pmcid: 8238121
doi: 10.3389/fonc.2021.689829
Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17(10):1142–9.
pubmed: 27648547
doi: 10.1038/ni.3558
Muller E, Speth M, Christopoulos PF, Lunde A, Avdagic A, Oynebraten I, et al. Both type I and type II interferons can activate Antitumor M1 macrophages when combined with TLR stimulation. Front Immunol. 2018;9:2520.
pubmed: 30450098
pmcid: 6224375
doi: 10.3389/fimmu.2018.02520
Karimi K, Karimi Y, Chan J, Boudreau JE, Basset J, Chew MV, et al. Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity. Innate Immun. 2015;21(6):626–34.
pubmed: 25749844
doi: 10.1177/1753425915575078
Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(12):13587–98.
pubmed: 26871470
pmcid: 4924663
doi: 10.18632/oncotarget.7277
Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of Immunotherapy Response. Cancer Discov. 2017;7(7):675–93.
pubmed: 28630051
pmcid: 5659200
doi: 10.1158/2159-8290.CD-17-0226
Maio M, Covre A, Fratta E, Di Giacomo AM, Taverna P, Natali PG, et al. Molecular pathways: at the crossroads of Cancer epigenetics and Immunotherapy. Clin Cancer Res. 2015;21(18):4040–7.
pubmed: 26374074
doi: 10.1158/1078-0432.CCR-14-2914
Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med. 2007;204(6):1303–10.
pubmed: 17502663
pmcid: 2118605
doi: 10.1084/jem.20062129
Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–64.
pubmed: 32771088
doi: 10.1016/S1470-2045(20)30324-7
Drew Y, Kim JW, Penson RT, O’Malley DM, Parkinson C, Roxburgh P, et al. Olaparib plus Durvalumab, with or without Bevacizumab, as treatment in PARP inhibitor-naive platinum-sensitive relapsed ovarian Cancer: a phase II Multi-cohort Study. Clin Cancer Res. 2024;30(1):50–62.
pubmed: 37939124
doi: 10.1158/1078-0432.CCR-23-2249
Harter P, Bidziński M, Colombo N, Floquet A, Pérez MJR, Kim JW et al. DUO-O: a randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients. J Clin Oncol 2019.
Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-arm phases 1 and 2 trial of Niraparib in Combination with Pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5(8):1141–9.
pubmed: 31194228
pmcid: 6567832
doi: 10.1001/jamaoncol.2019.1048
Randall LM, O’Malley DM, Monk BJ, Coleman RL, Gaillard S, Adams S, et al. Niraparib and Dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a phase II study (MOONSTONE/GOG-3032). Gynecol Oncol. 2023;178:161–9.
pubmed: 37890345
doi: 10.1016/j.ygyno.2023.10.005
Jin N, Xia Y, Gao Q. Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (review). Int J Oncol 2023, 62(2).
Ngoi NYL, Leo E, O’Connor MJ, Yap TA. Development of next-generation poly(ADP-Ribose) polymerase 1-Selective inhibitors. Cancer J. 2021;27(6):521–8.
pubmed: 34904816
doi: 10.1097/PPO.0000000000000556
Noordermeer SM, van Attikum HPARP, Inhibitor Resistance. A tug-of-war in BRCA-Mutated cells. Trends Cell Biol. 2019;29(10):820–34.
pubmed: 31421928
doi: 10.1016/j.tcb.2019.07.008
Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G. Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer. Drug Resist Updat. 2021;55:100744.
pubmed: 33551306
doi: 10.1016/j.drup.2021.100744
Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19(1):107.
pubmed: 32563252
pmcid: 7305609
doi: 10.1186/s12943-020-01227-0
Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest. 2019;129(3):1211–28.
pubmed: 30589644
pmcid: 6391116
doi: 10.1172/JCI123319
Buttarelli M, Ciucci A, Palluzzi F, Raspaglio G, Marchetti C, Perrone E, et al. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients. J Exp Clin Cancer Res. 2022;41(1):50.
pubmed: 35120576
pmcid: 8815250
doi: 10.1186/s13046-022-02265-w
Mukhopadhyay S, Vander Heiden MG, McCormick F. The Metabolic Landscape of RAS-Driven cancers from biology to therapy. Nat Cancer. 2021;2(3):271–83.
pubmed: 33870211
pmcid: 8045781
doi: 10.1038/s43018-021-00184-x
Therachiyil L, Anand A, Azmi A, Bhat A, Korashy HM, Uddin S. Role of RAS signaling in ovarian cancer. F1000Res. 2022;11:1253.
pubmed: 36451660
pmcid: 9669513
doi: 10.12688/f1000research.126337.1
Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer. 2008;99(12):2020–8.
pubmed: 19018267
pmcid: 2607229
doi: 10.1038/sj.bjc.6604783
Yang B, Li X, Fu Y, Guo E, Ye Y, Li F, et al. MEK Inhibition remodels the Immune Landscape of Mutant KRAS Tumors to overcome resistance to PARP and Immune Checkpoint inhibitors. Cancer Res. 2021;81(10):2714–29.
pubmed: 33589518
pmcid: 8265237
doi: 10.1158/0008-5472.CAN-20-2370
Mukhopadhyay S, Saqcena M, Foster DA. Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation. Oncoscience. 2015;2(10):807–8.
pubmed: 26682255
pmcid: 4671930
doi: 10.18632/oncoscience.253
Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, Foster DA. Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle. PLoS ONE. 2013;8(8):e74157.
pubmed: 23977397
pmcid: 3747087
doi: 10.1371/journal.pone.0074157
Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS ONE. 2009;4(3):e4715.
pubmed: 19262748
pmcid: 2650790
doi: 10.1371/journal.pone.0004715
Hudson CD, Savadelis A, Nagaraj AB, Joseph P, Avril S, DiFeo A, et al. Altered glutamine metabolism in platinum resistant ovarian cancer. Oncotarget. 2016;7(27):41637–49.
pubmed: 27191653
pmcid: 5173084
doi: 10.18632/oncotarget.9317
Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, et al. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis is an effective Synthetic Lethal Approach for Treating Chemoresistant ovarian cancers. Cancer Res. 2020;80(20):4514–26.
pubmed: 32859605
pmcid: 7572606
doi: 10.1158/0008-5472.CAN-19-3971